Cargando…

Association of thrombosis and mortality in patients with COVID-19 infections: a hospital-based observational study

OBJECTIVE: A hospital-based cross-sectional study on COVID-19 confirmed patients was conducted at the Aga Khan University Hospital, Karachi, Pakistan, from April to June 2021. Presence of thrombosis in these patients was compared with mortality. Platelet counts and D-dimer was also compared among su...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Sher M., Hanif, Sadaf, Iqbal, Madiha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389498/
https://www.ncbi.nlm.nih.gov/pubmed/36000085
http://dx.doi.org/10.1186/s43162-022-00153-5
Descripción
Sumario:OBJECTIVE: A hospital-based cross-sectional study on COVID-19 confirmed patients was conducted at the Aga Khan University Hospital, Karachi, Pakistan, from April to June 2021. Presence of thrombosis in these patients was compared with mortality. Platelet counts and D-dimer was also compared among survivor and non-survivor to identify the marker for severity of the disease. RESULTS: Sixty-six patients were enrolled in the study and the mean age of the patients was 62.3 years and 45 patients (68.2%) were male. Pulmonary embolism was identified in 32 patients (48.5%) while non-pulmonary thrombosis occurred in 5 of the admitted patients (7.6%). In our study, mortality occurred in 34 patients (51.5%). Pulmonary embolism was identified in 20 recovered patients (62.5%) and 10 patients died (p value 0.03). Four patients (80%) with non-pulmonary thrombosis were non-survivors (p value 0.05). Median platelets were 73 in non-survivors and 109.5 in survivors (p value < 0.01). Both the groups had a median D-dimer of 3.8 (p value 0.024). CONCLUSION: Based on our study, we conclude that COVID-19 infection has the potential to cause hypercoagulable states. It increases the risk of thrombosis and with thrombosis it has a higher mortality rate. Thrombocytopenia is a biomarker with an adverse prognosis in these patients.